glp-1 drugs moa Mechanism of action of agonists – My Endo Consult Recent updates on GLP-1 agonists:

doi: 10.1210/en.2003-0007

C., Edmondson, S., Feeney, W

Gastrointestinal (GI) side effects are incredibly common with GLP-1 use and are often among the biggest challenges

CVOTs primarily proved cardiovascular safety and tolerability of different GLP-1 receptor agonists, but also showed cardiovascular benefit of specific drugs

In December 2025, the administration also introduced the BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) model, a five year CMS Innovation Center (CMMI) model that intends to expand access to obesity drugs in Medicaid and Medicare by negotiating lower GLP-1 prices with manufacturers

Use it as a snapshot, then keep the surrounding routine in Lina